News First-in-class hay fever immunotherapy backed for NHS use A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.
News First intranasal anaphylaxis drug launches in Germany An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first market, by ALK-Abello.
News Dust mite allergy sufferers set for a new NHS treatment ALK-Abello's Acarizax for dust mite allergy should soon be available through the NHS in England, Wales and Northern Ireland, but not in Scotland.
News Capricor sues partner Nippon Shinyaku in DMD therapy spat Capricor has filed a lawsuit seeking to split from its commercial partner for Duchenne muscular dystrophy therapy, deramiocel, in the US.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.